Physician profile
Edwin Bello
NPI 1295741379
$2,742.09
in general payments reported to CMS, 2019-2025
30 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $345 · 2021: $393 · 2022: $621 · 2023: $403 · 2024: $343 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $884.93 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Astellas Pharma US INC | $263.24 | 2022-2025 | Veozah |
| Coopersurgical, INC. | $218.38 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $198.23 | 2022-2024 | |
| Scynexis, INC. | $130.12 | 2021-2022 | |
| Organon LLC | $117.88 | 2022-2025 | Nexplanon |
| Mylan Pharmaceuticals INC. | $91.15 | 2020-2022 | |
| Agile Therapeutics, INC. | $76.21 | 2022-2024 | Twirla |
| Minerva Surgical, INC | $75.37 | 2025 | |
| Exeltis, USA INC. | $72.81 | 2021-2024 | Slynd |
| Pfizer INC. | $72.62 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.53 | 2019-2025 | |
| Biogen, INC. | $58.41 | 2025 | Zurzuvae |
| Evofem Biosciences, INC. | $56.64 | 2021-2023 | Phexxi |
| Sumitomo Pharma America, INC. | $50.86 | 2024 | Myfembree |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $48.28 | 2022-2024 | Aptima, Acessa Provu System |
| Myovant Sciences INC. | $36.17 | 2022 | |
| Avion Pharmaceuticals | $30.77 | 2019-2020 | |
| Therapeuticsmd, INC. | $21.49 | 2021 | |
| Shield Therapeutics INC | $20.49 | 2023 | Accrufer |
| Applied Medical Resources Corporation | $20.32 | 2023 | |
| Meditrina | $20.21 | 2024-2025 | |
| Medline Industries Lp | $17.78 | 2024 | |
| Radius Health, INC. | $16.18 | 2020 | |
| Smith+Nephew, INC. | $15.87 | 2025 | Pico 14 |
| Dysis Medical, INC. | $14.69 | 2023 | Dysis V3 Digital Coploscope, Dysis Ultra 2.0, Dysis View |
| Merck Sharp & Dohme LLC | $14.43 | 2025 | Gardasil 9 |
| Daiichi Sankyo INC. | $13.03 | 2019 | |
| Channel Medsystems, INC. | $12.20 | 2024 | |
| Amag Pharmaceuticals, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Bello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.